CorMedix Inc. (CRMD)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1410098 · fiscal year ends in Dec
Closing price $7.63 on 29 Oct 2026; 52-week range $6.25 to $12.73.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $462.2M
- Net income, last twelve months
- $187.2M
- Earnings per share
- $2.14
- Gross margin
- 82.8%
- Operating margin
- 47.0%
- Net margin
- 40.5%
- Free cash flow
- $250.4M
- Return on equity
- 40.6%
- Market value
- $593.0M
- Price to earnings
- 3.6x
- Cash
- $256.7M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 77.7M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $311.7M | $150.1M | $163.1M | $2.04 | $172.8M | 10-K filed 5 Mar 2026 |
| FY2024 | 31 Dec 2024 | $43.5M | -$22.4M | -$17.9M | -$0.30 | -$50.7M | 10-K filed 25 Mar 2025 |
| FY2022 | 31 Dec 2022 | $65.4K | -$30.6M | -$29.7M | -$0.74 | -$24.6M | 10-K filed 30 Mar 2023 |
| FY2021 | 31 Dec 2021 | $190.9K | -$29.4M | -$28.2M | -$0.75 | -$22.6M | 10-K filed 29 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $101.9M | $26.0M | $0.29 |
| Q1 FY2026 | 31 Mar 2026 | $127.4M | $38.6M | $0.43 |
| Q4 FY2025 | 31 Dec 2025 | $128.6M | $14.0M | $0.16 |
| Q3 FY2025 | 30 Sep 2025 | $104.3M | $108.6M | $1.26 |
| Q2 FY2025 | 30 Jun 2025 | $39.7M | $19.8M | $0.28 |
| Q1 FY2025 | 31 Mar 2025 | $39.1M | $20.6M | $0.30 |
| Q3 FY2024 | 30 Sep 2024 | $11.5M | -$2.8M | -$0.05 |
| Q2 FY2024 | 30 Jun 2024 | $806.1K | -$14.2M | -$0.25 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| DefenCath | $258.8M | 83.0% |
| Melinta Portfolio | $45.5M | 14.6% |
| Contract revenue | $7.4M | 2.4% |
Company events
The newest 8-K filings of 291 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 19 Oct 2026 | 8-K | Investor update | 7.01, 9.01 |
| 13 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 7 Aug 2026 | 8-K | Other events | 8.01, 9.01 |
| 2 Jul 2026 | 8-K | Other events | 8.01 |
| 1 Jul 2026 | 8-K | Auditor change | 4.01 |
| 24 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 8 Jun 2026 | 8-K | Investor update | 7.01, 9.01 |
| 14 May 2026 | 8-K | Results | 2.02, 9.01 |
| 27 Apr 2026 | 8-K | Investor update | 7.01, 9.01 |
| 6 Mar 2026 | 8-K | Investor update | 7.01, 9.01 |
| 5 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 8 Jan 2026 | 8-K | Results, Leadership change, Other events | 2.02, 5.02, 8.01, 9.01 |
Every filing
The newest filings with the SEC of 527 held.
| Filed | Form | Period |
|---|---|---|
| 19 Oct 2026 | 8-K | 19 Oct 2026 |
| 13 Aug 2026 | 10-Q | 30 Jun 2026 |
| 13 Aug 2026 | 8-K | 13 Aug 2026 |
| 7 Aug 2026 | 8-K | 7 Aug 2026 |
| 2 Jul 2026 | 8-K | 29 Jun 2026 |
| 1 Jul 2026 | 8-K | 25 Jun 2026 |
| 25 Jun 2026 | S-8 POS | – |
| 24 Jun 2026 | 8-K | 23 Jun 2026 |
| 8 Jun 2026 | 8-K | 8 Jun 2026 |
| 14 May 2026 | 10-Q | 31 Mar 2026 |
| 14 May 2026 | 8-K | 14 May 2026 |
| 29 Apr 2026 | ARS | 31 Dec 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 21 Jan 2026 | Dillione Janet, Director | Sale under a trading plan | 10,000 | $6.88 | $68.8K | 38,473 | 22 Jan 2026 |
| 30 Dec 2025 | Dunton Alan W, Director | Sale under a trading plan | 20,000 | $13.00 | $260.0K | 40,250 | 2 Jan 2026 |
| 18 Dec 2025 | Todisco Joseph, Chief Executive Officer | Sale under a trading plan | 30,000 | $12.00 | $360.0K | 509,496 | 19 Dec 2025 |
| 9 Dec 2025 | Dillione Janet, Director | Sale under a trading plan | 34,000 | $12.00 | $408.0K | 48,473 | 11 Dec 2025 |
| 9 Dec 2025 | Lefkowitz Steven W, Director | Sale outside a trading plan | 40,000 | $11.88 | $475.2K | 80,498 | 10 Dec 2025 |
| 2 Dec 2025 | Dillione Janet, Director | Sale under a trading plan | 46,657 | $10.00 | $466.6K | 48,473 | 4 Dec 2025 |
| 24 Nov 2025 | Dillione Janet, Director | Sale outside a trading plan | 26,343 | $9.93 | $261.6K | 48,473 | 26 Nov 2025 |
| 14 Nov 2025 | Dillione Janet, Director | Sale outside a trading plan | 30,000 | $11.42 | $342.6K | 48,473 | 18 Nov 2025 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 21 Jan 2026 | Janet Dillione, Director | 10,000 | $68.5K | 21 Jan 2026 |
| 30 Dec 2025 | Alan Dunton, Director | 20,000 | $259.4K | 30 Dec 2025 |
| 18 Dec 2025 | Joseph Todisco, Officer | 30,000 | $359.1K | 18 Dec 2025 |
| 9 Dec 2025 | Janet Dillione, BOD | 34,000 | $408.0K | 9 Dec 2025 |
| 9 Dec 2025 | Lefkowitz Steven W, Director | 40,000 | $450.4K | 9 Dec 2025 |
| 24 Nov 2025 | Janet Dillione, Director | 73,000 | $727.9K | 24 Nov 2025 |
| 14 Nov 2025 | Dillione Janet, Director | 30,000 | $328.2K | 14 Nov 2025 |
| 10 Nov 2025 | Erin Mistry, Former Officer | 13,543 | $148.7K | 10 Nov 2025 |
| 6 Nov 2025 | Erin Mistry, Former Officer | 13,908 | $152.5K | 6 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 12 Jun 2026 | SHAIBATALHAMD AYMEN ABDALKADER | 13G amended | 5.9% | 4.6M |
| 12 Jun 2026 | SHAIBATALHAMD AYMEN ABDALKADER | 13G amended | 5.9% | 4.6M |
| 15 May 2026 | Deep Track Capital, LP | 13G amended | 7.94% | 6.3M |
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 2 Jan 2026 | SHAIBATALHAMD AYMEN ABDALKADER | 13G amended | 5.8% | 4.6M |
| 1 Dec 2025 | Deep Track Capital, LP | 13G | 6.29% | 5.0M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 14.7M | -4.91% | 12.67 |
| 30 Sep 2026 | 15.4M | -4.81% | 18.9 |
| 15 Sep 2026 | 16.2M | +1.06% | 18.49 |
| 31 Aug 2026 | 16.0M | -6.52% | 12.98 |
| 14 Aug 2026 | 17.1M | +5.32% | 11.05 |
| 31 Jul 2026 | 16.3M | +6.08% | 17.1 |
| 15 Jul 2026 | 15.3M | +2.81% | 17.01 |
| 30 Jun 2026 | 14.9M | +2.93% | 7.75 |
Funds that hold it
From each fund's latest Form 13F.
215 funds held it at 30 Jun 2026: 93 added and 58 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 6,324,111 | $49.6M | +356,536 |
| Deep Track Capital, LP | 6,274,076 | $49.3M | 0 |
| Vanguard Capital Management LLC | 3,135,075 | $24.6M | +5,419 |
| State Street Corp. | 2,316,845 | $18.2M | +125,002 |
| Royce & Associates LP | 2,176,362 | $17.1M | +288,830 |
| Geode Capital Management, LLC | 1,947,014 | $15.3M | +130,107 |
| UBS Group AG | 1,877,940 | $14.7M | +339,695 |
| Oberweis Asset Management Inc. | 1,323,915 | $10.4M | +112,800 |
| Alyeska Investment Group, L.P. | 850,000 | $6.7M | 0 |
| Marshall Wace, LLP | 779,535 | $6.1M | +276,570 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B